Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

[1]  F. Ismail-Beigi,et al.  Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial , 2020, Advances in Therapy.

[2]  F. Pattou,et al.  Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. , 2020, Gastroenterology.

[3]  J. Hsiang,et al.  SGLT2 inhibitors in liver patients. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Yan-Ling He,et al.  Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial , 2020, Clinical pharmacology and therapeutics.

[5]  H. Bays,et al.  Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity , 2020, Obesity.

[6]  C. Sirlin,et al.  Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. , 2019, The Journal of clinical investigation.

[7]  L. Adams,et al.  Lifestyle modification in NAFLD/NASH: Facts and figures , 2019, JHEP reports.

[8]  B. Neuschwander‐Tetri,et al.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2019, The Lancet.

[9]  Yan-Ling He,et al.  The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes , 2019, Diabetes, obesity & metabolism.

[10]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[11]  S. Kar,et al.  SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review , 2019, World journal of diabetes.

[12]  C. Sirlin,et al.  Acetyl‐CoA Carboxylase Inhibitor GS‐0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  R. Loomba,et al.  GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[14]  M. Moriguchi,et al.  Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis , 2018, Diabetes, metabolic syndrome and obesity : targets and therapy.

[15]  Kunihiro Suzuki,et al.  Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease , 2018, Diabetes, obesity & metabolism.

[16]  L. Lind,et al.  Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study , 2018, Diabetologia.

[17]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[18]  A. Mithal,et al.  Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) , 2018, Diabetes Care.

[19]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[20]  Jun Yu,et al.  Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. , 2016, The lancet. Gastroenterology & hepatology.

[21]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[22]  R. Fenton,et al.  Sodium-glucose cotransport , 2015, Current opinion in nephrology and hypertension.

[23]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[24]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[25]  Weilin Wang,et al.  The Performance of Enhanced Liver Fibrosis (ELF) Test for the Staging of Liver Fibrosis: A Meta-Analysis , 2014, PloS one.

[26]  Sabrina Fox‐Bosetti,et al.  Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging , 2013, Journal of magnetic resonance imaging : JMRI.

[27]  K. Kim,et al.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise , 2013, Diabetes, obesity & metabolism.

[28]  A. Gamst,et al.  Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. , 2009, Radiology.

[29]  Guías de Práctica Clínica.  European Association for the Study of the Liver , 1971 .

[30]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[31]  S. Horgan,et al.  Estimation of Hepatic Proton-Density Fat Fraction by Using MR Imaging at 3.0 T 1 , 2011 .

[32]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.